Technical Name An novel drug for preventing chemical-induced intestinal damage and colorectal cancer
Project Operator Kaohsiung medical university
Project Host
Glucuronidation is a major pathway for detoxification in the liver. Drugs and toxic chemicals are conjugated with glucuronide acid to be inactive form through this pathway. However, when glucuronide conjugates enter the intestine, they are reactivated by E. coli expressing G (eG) back to toxic form, thus damaging the intestine and inducing diarrhea, which is likely to cause carcinogenesis and colorectal cancer. The current treatment is using antidiarrheal agent to release the diarrhea symptom but the damage still persist. In addition, there are no clinical drug been developed to prevent colon cancer. In order to meet the unmet clinical need, we have successfully developed eβG specific inhibitor as a novel drug for preventing chemical-induced damage and colon cancer. The inhibitor can be developed as:
1.Chemotherapy adjuvant, be combined with chemo drug to prevent chemotherapy -induced intestinal damage and diarrhea, thus improving patients’ quality of life and increasing patient’s drug tolerance to increase therapy efficacy.
2.Chemoprevention drug, to prevent reactivating of the carcinogen in the intestine and thus reducing chemo-induced carcinogenesis and colon cancer.
We have applied the novel inhibitor and its derivatives and their function for patent protection, including PCT, provisional application for patent in the US, and the Taiwan (ROC) patent.
Scientific Breakthrough
Industrial Applicability
  • Contact
other people also saw